These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22300007)

  • 1. The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.
    Barrett TD; Lagaud G; Wagaman P; Freedman JM; Yan W; Andries L; Rizzolio MC; Morton MF; Shankley NP
    Br J Pharmacol; 2012 Jul; 166(5):1684-93. PubMed ID: 22300007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
    Morton MF; Barrett TD; Freedman J; Li L; Rizzolio MC; Prendergast CE; Wu X; Moreno V; Pyati J; Figueroa K; Cagnon L; Lagaud G; Ver Donck L; Ghoos E; Allison B; Rabinowitz MH; Shankley NP
    J Pharmacol Exp Ther; 2011 Jul; 338(1):328-36. PubMed ID: 21493750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
    Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
    Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
    Makovec F; Revel L; Letari O; Mennuni L; Impicciatore M
    Eur J Pharmacol; 1999 Mar; 369(1):81-90. PubMed ID: 10204685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfusion into gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Drozdowicz D; Kwiecieñ S; Pajdo R; Bielanski W; Hahn EG
    Eur J Pharmacol; 2000 Jun; 398(1):147-58. PubMed ID: 10856459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat.
    Hayward NJ; Harding M; Lloyd SA; McKnight AT; Hughes J; Woodruff GN
    Br J Pharmacol; 1991 Dec; 104(4):973-7. PubMed ID: 1687371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of inhibition of gastric acid secretion by omeprazole and ranitidine in gastric fistula rats.
    Seensalu R; Girma K; Romell B; Nilsson G
    Eur J Pharmacol; 1990 May; 180(1):145-52. PubMed ID: 2364999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression.
    Nishida A; Kobayashi-Uchida A; Akuzawa S; Takinami Y; Shishido T; Kamato T; Ito H; Yamano M; Yuki H; Nagakura Y
    Am J Physiol; 1995 Nov; 269(5 Pt 1):G699-705. PubMed ID: 7491961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
    Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gastrin/CCK-B receptor antagonists for a novel antiulcer agent].
    Miyata K; Nishida A; Honda K
    Nihon Yakurigaku Zasshi; 1995 Sep; 106(3):171-80. PubMed ID: 8529962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentagastrin gastroprotection against acid is related to H2 receptor activation but not acid secretion.
    Tanaka S; Akiba Y; Kaunitz JD
    Gut; 1998 Sep; 43(3):334-41. PubMed ID: 9863477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained cholecystokinin-B/gastrin receptor blockade does not impair basal or histamine-stimulated acid secretion in chronic gastric fistula rats.
    Ding XQ; Kitano M; Håkanson R
    Pharmacol Toxicol; 1998 Apr; 82(4):177-82. PubMed ID: 9584331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
    Nagaya H; Inatomi N; Satoh H
    Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cimetidine and omeprazole accelerate gastric ulcer healing by an increase in gastrin secretion.
    Ito M; Segami T; Inaguma K; Suzuki Y
    Eur J Pharmacol; 1994 Oct; 263(3):253-9. PubMed ID: 7843262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased gastric acid secretion in cholecystokinin-1 receptor-deficient Otsuka Long-Evans Tokushima fatty rats.
    Kanagawa K; Nakamura H; Murata I; Yosikawa I; Otsuki M
    Scand J Gastroenterol; 2002 Jan; 37(1):9-16. PubMed ID: 11843043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
    Kinoshita M; Saito N; Tamaki H
    Eur J Pharmacol; 1997 Mar; 321(3):325-32. PubMed ID: 9085044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of long-term administration of antisecretary drugs on rat gastric histamine synthesis and acid secretion--compare with omeprazole and cimetidine].
    Morita R; Harasawa S; Miwa T; Matsumoto M
    Nihon Shokakibyo Gakkai Zasshi; 1992 Oct; 89(10):2551-8. PubMed ID: 1404968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked increase in gastric acid secretory capacity after omeprazole treatment.
    Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
    Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.